HIGHLIGHTS
- who: Tobias Braun and collaborators from the Hospital Clu0131u00b4nic/IDIBAPS, SpainSchool (MHH), Hannover, Germany, University of Cologne, Faculty of Medicine and University have published the paper: Non-viral TRAC-knocked-in CD19KICAR-T and gp350KICAR-T cells tested against Burkitt lymphomas with type 1 or 2 EBV infection: In vivo cellular dynamics and potency, in the Journal: (JOURNAL)
- what: The studies aim specifically to demonstrate the feasibility and potency of KICAR-T_cells against EBV+ BL. As mentioned above, the main reason for the lower efficacy of gp350KICAR-T_cells compared with CD19KICAR-T_cells was most likely . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.